Repros Therapeutics (NASDAQ:RPRX), Enzymotec Ltd. (NASDAQ:ENZY) and Covisint Corp. (NASDAQ:COVS) are making big gains this Thursday. Voltari Corp. (NASDAQ:VLTC), Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and Scorpio Bulkers Inc. (NYSE:SALT) are posting losses.
ValueWalk's Raul Panganiban with Maurits Pot, Founder and CEO of Dawn Global. Before this he was Partner at Kingsway Capital, a frontier market specialist with over 2 billion AUM. In the interview, we discuss his approach to investing and why investors should look into frontier and emerging markets. Q2 2021 hedge fund letters, conferences and Read More
Repros Therapeutics Climbs on FDA Application Approval
Repros Therapeutics climbed +9.31% early in the day after announcing yesterday that the FDA has accepted its new drug application. Farallon Capital has a small stake in the biotech company.
Enzymotec Ltd. rallied +7.34% this morning, though year-to-date its performance remains flat. John Paulson owns 4.24 million ENZY shares – 19.27% of the company.
Covisint Corp. gained +7.14% this Thursday, though the stock is still down more than -20% year-to-date. Short interest in COVS is on the rise, and it hit a new 52-week low last month. This is another Farallon Capital pick.
Voltari Corp. Dips
Voltari Corp. dipped -7.6% this morning, though it’s still up an incredible +182.5% over the past five days. The explanation: Carl Icahn’s disclosure of what appears to be an activist stake in the firm.
Xenon Pharmaceuticals tumbled -4.26% and is down -15% YTD. Wilbur Ross has a stake in the company.
Scorpio Bulkers Inc. fell -4.07% early in the day, though it’s still up about +7% in 2015. As of the end of the fourth quarter of last year, Marc Lasry holds 16.53 million SALT shares. The company has a 3.01% in his public equity portfolio.